Published in Adv Pharmacol on January 01, 1997
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 5.12
Prostaglandins and cancer. Gut (2005) 3.44
gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A (2000) 2.29
Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med (2001) 2.22
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med (2003) 1.69
Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol (1999) 1.65
Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci (2007) 1.64
Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer (2007) 1.35
Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia (2001) 1.32
Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett (2008) 1.32
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators". Biochimie (2010) 1.07
An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01
Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila) (2011) 1.00
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut (2001) 0.99
Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol (2009) 0.98
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia (2012) 0.98
Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol (2004) 0.97
DNA repair is indispensable for survival after acute inflammation. J Clin Invest (2012) 0.96
National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia (2002) 0.95
The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs (2006) 0.93
Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell (2009) 0.93
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) (2011) 0.92
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res (2010) 0.91
Current perspectives in NSAID-induced gastropathy. Mediators Inflamm (2013) 0.91
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia (2003) 0.91
Cox-2 gene expression in chemically induced skin papillomas cannot predict subsequent tumor fate. Mol Oncol (2010) 0.90
Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res (2005) 0.88
Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. Cancer Prev Res (Phila) (2010) 0.88
Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg (2001) 0.88
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep (2012) 0.87
Therapeutic Implications of PPARgamma in Human Osteosarcoma. PPAR Res (2010) 0.86
Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. Dig Dis Sci (2015) 0.85
Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc (2014) 0.85
Relation of the expression of cyclooxygenase-2 in colorectal adenomas and adenocarcinomas to angiogenesis and prognosis. J Korean Soc Coloproctol (2010) 0.85
Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell (2011) 0.85
Modeling of non-steroidal anti-inflammatory drug effect within signaling pathways and miRNA-regulation pathways. PLoS One (2013) 0.83
Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70. Cell Death Dis (2014) 0.82
Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev (2013) 0.82
Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer. J Nucleic Acids (2009) 0.82
The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon. Nutr Rev (2011) 0.82
Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int J Colorectal Dis (2003) 0.81
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am (2010) 0.81
Beta-catenin is involved in alterations in mitochondrial activity in non-transformed intestinal epithelial and colon cancer cells. Br J Cancer (2009) 0.80
Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm (2002) 0.79
Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br J Cancer (1999) 0.78
Targeting microenvironment in cancer therapeutics. Oncotarget (2016) 0.78
Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. J Steroid Biochem Mol Biol (2015) 0.76
The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage. Biochem J (2003) 0.76
Leukotriene D4-induced Caco-2 cell proliferation is mediated by prostaglandin E2 synthesis. Physiol Rep (2015) 0.76
Targeting cyclooxygenase-2 with sodium butyrate and NSAIDs on colorectal adenoma/carcinoma cells. World J Gastroenterol (2004) 0.76
Validity of APCS score as a risk prediction score for advanced colorectal neoplasia in Chinese asymptomatic subjects: A prospective colonoscopy study. Medicine (Baltimore) (2016) 0.75
Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers (Basel) (2011) 0.75
Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. Cancer Inform (2007) 0.75
11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis. J Oncobiomarkers (2013) 0.75
Alleviating Promotion of Inflammation and Cancer Induced by Nonsteroidal Anti-Inflammatory Drugs. Int J Inflam (2017) 0.75
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell (1995) 6.69
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A (1997) 4.84
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem (2001) 3.40
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest (2000) 3.03
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem (1997) 2.66
Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev (1999) 2.37
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res (2000) 2.05
Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol (1996) 1.91
Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem (2000) 1.77
Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology (2000) 1.75
Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology (1996) 1.65
Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem (2000) 1.58
Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem (2001) 1.48
Global gene expression analysis to identify molecular markers of uterine receptivity and embryo implantation. J Biol Chem (2001) 1.43
A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology (1997) 1.35
The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer (1995) 1.32
Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest (1997) 1.25
Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.24
Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog (1999) 1.23
Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res (1997) 1.23
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene (2001) 1.20
Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem (2001) 1.20
Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys (1995) 1.20
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
Nuclear translocation of beta-catenin in hereditary and carcinogen-induced intestinal adenomas. Carcinogenesis (1998) 1.16
Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci (1998) 1.15
Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology (2000) 1.13
Cytochrome P-450 arachidonic acid epoxygenase. Regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem (1992) 1.12
Aspirin, NSAIDS, and colon cancer prevention: mechanisms? Gastroenterology (1998) 1.11
Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res (1998) 1.09
Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem (2000) 1.09
Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol (1997) 1.09
Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis (1999) 1.07
A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res (2001) 1.04
The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry (1995) 1.03
A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia (2001) 0.99
Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia (2001) 0.98
Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem (2001) 0.98
Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis (1998) 0.97
Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 arachidonic acid epoxygenase. J Biol Chem (1993) 0.96
The role of COX-2 in intestinal cancer. Ann N Y Acad Sci (1999) 0.96
Induction of synthesis of cholesterol side chain cleavage cytochrome P-450 by adrenocorticotropin in cultured bovine adrenocortical cells. J Biol Chem (1981) 0.95
Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ (1997) 0.94
Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep (1999) 0.93
Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia (1999) 0.90
Eicosanoids and the large intestine. Prostaglandins Other Lipid Mediat (2000) 0.89
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res (1997) 0.88
Evidence for a higher molecular weight precursor of cholesterol side-chain-cleavage cytochrome P-450 and induction of mitochondrial and cytosolic proteins by corticotropin in adult bovine adrenal cells. Proc Natl Acad Sci U S A (1981) 0.88
Transformation of intestinal epithelial cells by chronic TGF-beta1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene (1999) 0.88
Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology (1998) 0.86
The role of COX-2 in intestinal cancer. Expert Opin Investig Drugs (1999) 0.84
Combinations for cancer prevention. Nat Med (2000) 0.84
Regulation of 12-lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis induced by sodium butyrate. Arch Biochem Biophys (1999) 0.82
Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am (2001) 0.82
Translational studies on Cox-2 inhibitors in the prevention and treatment of colon cancer. Ann N Y Acad Sci (2000) 0.81
In vivo immediate early gene expression induced in intestinal and colonic mucosa by feeding. FEBS Lett (1991) 0.81
The molecular basis for prevention of colorectal cancer. Clin Colorectal Cancer (2001) 0.80
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer (2003) 0.80
Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene (2011) 0.80
Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenomas. Gastroenterology (1995) 0.79
Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol (2001) 0.79
The molecular basis of colorectal carcinogenesis. Curr Opin Gastroenterol (1999) 0.77
Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol (2000) 0.77
Antioxidant effect of acetaminophen in rat liver. Biochem Pharmacol (1983) 0.76
Cyclooxygenease-2 and hepatocellular carcinoma: is it a target for prevention? Clin Cancer Res (2001) 0.75
Altered heme environments in opossum and rabbit methemoglobins. Z Naturforsch C (1982) 0.75
Current concepts in colorectal cancer prevention. Compr Ther (1997) 0.75
Induction of rabbit cyclooxygenase 2 in the anterior uvea following glaucoma filtration surgery. Curr Eye Res (1997) 0.75